KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Cash & Equivalents (2016 - 2026)

Edwards Lifesciences has reported Cash & Equivalents over the past 17 years, most recently at $2.9 billion for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 3.52% year-over-year to $2.9 billion; the TTM value through Dec 2025 reached $2.9 billion, down 3.52%, while the annual FY2025 figure was $2.9 billion, 3.52% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $2.9 billion at Edwards Lifesciences, up from $2.7 billion in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $3.7 billion in Q3 2024 and troughed at $11.7 million in Q4 2023.
  • A 5-year average of $1.7 billion and a median of $1.3 billion in 2021 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: tumbled 98.46% in 2023 and later soared 25927.35% in 2024.
  • Year by year, Cash & Equivalents stood at $862.8 million in 2021, then fell by 11.74% to $761.5 million in 2022, then tumbled by 98.46% to $11.7 million in 2023, then soared by 25927.35% to $3.0 billion in 2024, then dropped by 3.52% to $2.9 billion in 2025.
  • Business Quant data shows Cash & Equivalents for EW at $2.9 billion in Q4 2025, $2.7 billion in Q3 2025, and $3.3 billion in Q2 2025.